JPRN-jRCTs031210557
Recruiting
Phase 2
A single-arm, phase II study to evaluate the effect of low-dose atovaquone on the prevention of pneumocystis pneumonia in patients with rheumatic diseases treated with corticosteroids
Furuta Syunsuke0 sites50 target enrollmentJanuary 18, 2022
ConditionsRheumatic Diseases
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Rheumatic Diseases
- Sponsor
- Furuta Syunsuke
- Enrollment
- 50
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients who meet all of the following criteria are eligible.
- •1\) Age 20 years or older (regardless of gender)
- •2\) Patients who are scheduled to start, or have started within 10 days of starting, prednisolone at a dose of 0\.5 mg/kg/day or higher or equivalent corticosteroids for the treatment of rheumatic diseases.
- •3\) Patients who have been fully informed about participation in the study prior to the start of the study and who have provided written consent.
Exclusion Criteria
- •Patients who meet any of the following criteria should be excluded.
- •1\) Patients with a history of continuous use of corticosteroids within 6 months (excluding patients who meet the inclusion criteria 2\)
- •2\) Patients who are already taking ST combination, atovaquone, pentamidine, or dapsone
- •3\) Patients with a history of hypersensitivity to atovaquone
- •4\) Patients with uncontrolled complications
- •5\) Patients whose AST or ALT exceeds three times the upper limit of the institutional reference value
- •6\) Patients who are pregnant, may become pregnant, within 28 days postpartum, or breast\-feeding
- •7\) Any other patient who is judged by the investigator or sub\-investigator to be inappropriate for the safe conduct of the study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
on-randomized clinical trial to assess the effect of a medication against cytomegalovirus in patients who are not infected originally cytomegalovirus but who have received renal transplantation from donors that are infected by cytomegalovirus.CMV seronegative patients that have received kidney allografts from CMV seropositive donorsV01-Y98RBR-8gcx9mTheraclone Sciences, Inc
Withdrawn
Not Applicable
A single arm phase II trial to evaluate the efficacy of Poziotinib, pan HER inhibitor in recurrent/metastatic esophageal cancerKCT0003833Yonsei University Health System, Severance Hospital49
Not yet recruiting
Phase 2
Biomarcer-2 :Biomarker informed optimal management of advanced RAS wild type colorectal cancerAdvanced RAS Wild type right sided Colorectal cancerCancer - Bowel - Back passage (rectum) or large bowel (colon)ACTRN12623000874617Australasian Gastrointestinal Trials Group29
Active, not recruiting
Not Applicable
A single arm Phase II study to assess efficacy and safety of bevacizumab in combination with the standard therapy (interferon alfa-2a and vinblastine) as first-line treatment for patients with metastatic renal cell cancer (Bevacizumab with standard therapy in RCC) - Bevacizumab with standard therapy in RCCMetastatic renal cell cancerEUCTR2005-006161-13-DERoche Pharma AG
Active, not recruiting
Phase 1
A phase II study of linperlisib (YY-20394) in patients with relapsed or refractory peripheral T/NK cell or Cutaneous T Cell lymphomaCTIS2022-501431-16-00Shanghai Yingli Pharmaceutical Co. Ltd.107